MemberHealth Makes a Move

Three months in to Medicare Part D, the stand-alone drug insurance market is heavily concentrated. Not surprisingly, United has the biggest share. But one member of the top tier--MemberHealth--is an unlikely heavyweight.

Fifty-four different companies entered the stand-alone prescription drug insurance market under Medicare Part D Jan. 1. But, even before the program began, it was clear that not all 54 would be competing on an equal footing in the race for enrollment in 2006. A handful of companies dominated the initial enrollment in Part D, because they bid most aggressively to serve former Medicaid recipients who were randomly assigned to plans. (See "Medicare Market Share: Drug Plan Starts With Big Four," IN VIVO, October, 2005 Also see "Medicare Market Share: Drug Plan Starts With Big Four" - In Vivo, 1 October, 2005..)

Three months into the program, the market is even more concentrated. The top 10 plan sponsors represent about 90% of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

ACIP ‘Pivot’ May Mean Variable US Coverage For New Vaccines, Higher Copays

 
• By 

Clarity on payer responses to controversial vaccine recommendations from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices may be coming.

More from Pink Sheet

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.